{
	"kja6j2rpText": "W<span class=\"_ _c\"></span>ang G e<span class=\"_ _2\"></span>t al. 2<span class=\"_ _c\"></span>0<span class=\"_ _c\"></span>1<span class=\"_ _23\"></span>5<span class=\"_ _3\"></span><span class=\"fs1 v1\">1</span>",
	"kja6j2rqText": "<div style=\"letter-spacing:-1.4px;\">A randomized double<span class=\"_ _0\"></span>-blind, multinational, fi<span class=\"_ _0\"></span>xed-dos<span class=\"_ _0\"></span>e s<span class=\"_ _0\"></span>tudy of<span class=\"_ _0\"></span> Brintellix® compared&nbsp;to ac<span class=\"_ _0\"></span>tive<div>comparator (v<span class=\"_ _2\"></span>enlafax<span class=\"_ _0\"></span>ine SR) for ef<span class=\"_ _0\"></span>fic<span class=\"_ _0\"></span>ac<span class=\"_ _0\"></span>y and tolerabilit<span class=\"_ _0\"></span>y<span class=\"_ _0\"></span> in major depres<span class=\"_ _0\"></span>sive&nbsp;disorder patients &nbsp;<br>(MDD) (SOLUTION study).<br></div></div>",
	"kja6j2rrText": "Key inclusion criteria ",
	"kja6j2rsText": "P<span class=\"_ _c\"></span>atients, 18-65 years <br>of age, with a primary <br>diagnosis of<span class=\"_ _0\"></span> MDD <br>according to DSM IV-<span class=\"_ _3\"></span>TR<span class=\"_ _0\"></span> <br>criteria and a current major <br>depressive episode of &gt;3<span class=\"_ _0\"></span> <br>months’ duration ",
	"kja6j2rtText": "MADRS score ≥26 and <br>CGI-S score &gt;4 at <br>baseline",
	"kja6j2ruText": "One week ",
	"kja6j2rvText": "double-blind ",
	"kja6j2rwText": "taper period",
	"kja6j2rxText": "Back",
	"kja6j2ryText": "Brintellix® 10 mg/day (n=213)",
	"kja6j2rzText": "V<span class=\"_ _2\"></span>enlafaxine XR 150 mg/day<br>(n=230) <span class=\"ff3\">75 mg/day for first <br>4 days according to SmPC </span>",
	"kja6j2s0Text": "recommendations",
	"kja6j2s1Text": "Effic<span class=\"_ _0\"></span>acy and<span class=\"_ _0\"></span> <br><span class=\"ls39 ws9f\">tolerabilit<span class=\"_ _0\"></span>y<span class=\"_ _0\"></span> <br><span class=\"ls46 wsa0\">were assessed<span class=\"_ _0\"></span> <br></span><span class=\"ws61\">at baseline<span class=\"_ _0\"></span> <br></span></span>and af<span class=\"_ _0\"></span>ter <br><span class=\"ls1a wsb\">weeks 1, 2, 4<span class=\"_ _2\"></span>, <br>6 and 8</span>",
	"kja6j2s2Text": "Screening = 7 days <br><span class=\"ls29 wsa1\">Randomisation 1:<span class=\"_ _c\"></span>1 <br><span class=\"ls45 ws8c\">(<span class=\"_ _0\"></span>A<span class=\"_ _0\"></span>P<span class=\"_ _0\"></span>T<span class=\"_ _1\"></span>S n<span class=\"_ _0\"></span>=<span class=\"_ _1\"></span>42<span class=\"_ _0\"></span>4)</span></span>",
	"kja6j2s3Text": "4 week saf<span class=\"_ _2\"></span>ety<span class=\"_ _0\"></span> ",
	"kja6j2s4Text": "follow-<span class=\"_ _0\"></span>up",
	"kja6j2s5Text": "8-week double blind treatment period",
	"kja6j2s6Text": "Primary ef<span class=\"_ _0\"></span>ficac<span class=\"_ _0\"></span>y endpoint: <span class=\"ff3\">Ch<span class=\"_ _2\"></span>ange fr<span class=\"_ _2\"></span>om ba<span class=\"_ _2\"></span>seli<span class=\"_ _2\"></span>ne to w<span class=\"_ _2\"></span>eek 8 in <br><span class=\"ls37 ws7d\">MADRS tot<span class=\"_ _0\"></span>al s<span class=\"_ _0\"></span>core (analysis of<span class=\"_ _0\"></span> covariance<span class=\"_ _0\"></span> [ANCO<span class=\"_ _2\"></span>V<span class=\"_ _2\"></span>A] full-analy<span class=\"_ _0\"></span>sis<span class=\"_ _0\"></span> <br><span class=\"ls36 wsb\">set [<span class=\"_ _c\"></span>FAS<span class=\"_ _c\"></span>], last observation carrie<span class=\"_ _2\"></span>d forward [<span class=\"_ _c\"></span>LOC<span class=\"_ _2\"></span>F], usi<span class=\"_ _2\"></span>ng a non-<br><span class=\"ls47 ws6d\">inferiori<span class=\"_ _0\"></span>t<span class=\"_ _0\"></span>y margin<span class=\"_ _0\"></span> of +2<span class=\"_ _2\"></span>.5 po<span class=\"_ _0\"></span>int<span class=\"_ _0\"></span>s.</span></span></span></span>",
	"kja6j2s7Text": "Secondary e<span class=\"_ _0\"></span>f<span class=\"_ _0\"></span>ficac<span class=\"_ _0\"></span>y endpoint: <span class=\"ff3 ls5e wsa2\">Prespecified secondary <br><span class=\"ls36 wsb\">endpoi<span class=\"_ _2\"></span>nts inclu<span class=\"_ _2\"></span>de MADRS r<span class=\"_ _c\"></span>esponse an<span class=\"_ _2\"></span>d rem<span class=\"_ _2\"></span>ission ra<span class=\"_ _2\"></span>te<span class=\"_ _2\"></span>, <br>anxiety symptom<span class=\"_ _2\"></span>s (<span class=\"_ _2\"></span>HAM-A), C<span class=\"_ _c\"></span>GI, ov<span class=\"_ _2\"></span>eral<span class=\"_ _2\"></span>l functioni<span class=\"_ _2\"></span>ng (<span class=\"_ _c\"></span>SDS<span class=\"_ _c\"></span>)<span class=\"_ _0\"></span> <br>and he<span class=\"_ _2\"></span>alth-re<span class=\"_ _2\"></span>lat<span class=\"_ _2\"></span>ed qua<span class=\"_ _2\"></span>lity of life (<span class=\"_ _c\"></span>Q-LES-<span class=\"_ _0\"></span>Q)<span class=\"_ _c\"></span>.</span></span>",
	"Brintellix_80b33c5f72": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_80bcabd30a": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span> Wang G et al. Curr Med Res Opin 2015;31:785-794.</div>"
}
